Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers

View through CrossRef
<div>Abstract<p>Common lymphatic endothelial and vascular endothelial receptor-1 (Clever-1) is a multifunctional type-1 transmembrane protein that plays an important role in immunosuppression against tumors. Clever-1 is highly expressed in a subset of human tumor-associated macrophages and associated with poor survival. In mice, Clever-1 supports tumor growth and metastasis formation, and its deficiency or blockage induces T-cell–dependent killing of cancer cells. Therefore, targeting Clever-1 could lead to T-cell activation and restoration of immune response also in patients with cancer. This is studied in an on-going clinical trial [Macrophage Antibody To INhibit immune Suppression (MATINS); NCT03733990] in patients with advanced solid tumors where bexmarilimab, a humanized IgG4 antibody against human Clever-1, shows promising safety and efficacy.</p><p>Here, we report the humanization and nonclinical characterization of physicochemical properties, biological potency, and safety profile of bexmarilimab.</p><p>Bexmarilimab showed high affinity to Clever-1 on KG-1 cells and bound to Clever-1 on the surface of classical and intermediate monocytes derived from healthy human blood. Bexmarilimab inhibited the internalization of its natural ligand acetylated low-density lipoprotein into KG-1 cells and increased TNFα secretion from macrophages but did not impair phagocytic clearance. Bexmarilimab did not induce significant cytokine release in human whole-blood cultures, did not contain nonsafe immunogenic glycans, or show any significant binding to human Fcγ receptors or complement pathway component C1q. <i>In vivo</i>, bexmarilimab showed dose-dependent duration of monocyte Clever-1 receptor occupancy in cynomolgus monkeys but did not induce a cytokine storm up to a dose of 100 mg/kg.</p><p>In conclusion, these data support the clinical development of bexmarilimab for the restoration of immune response in cancers.</p></div>
Title: Data from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Description:
<div>Abstract<p>Common lymphatic endothelial and vascular endothelial receptor-1 (Clever-1) is a multifunctional type-1 transmembrane protein that plays an important role in immunosuppression against tumors.
Clever-1 is highly expressed in a subset of human tumor-associated macrophages and associated with poor survival.
In mice, Clever-1 supports tumor growth and metastasis formation, and its deficiency or blockage induces T-cell–dependent killing of cancer cells.
Therefore, targeting Clever-1 could lead to T-cell activation and restoration of immune response also in patients with cancer.
This is studied in an on-going clinical trial [Macrophage Antibody To INhibit immune Suppression (MATINS); NCT03733990] in patients with advanced solid tumors where bexmarilimab, a humanized IgG4 antibody against human Clever-1, shows promising safety and efficacy.
</p><p>Here, we report the humanization and nonclinical characterization of physicochemical properties, biological potency, and safety profile of bexmarilimab.
</p><p>Bexmarilimab showed high affinity to Clever-1 on KG-1 cells and bound to Clever-1 on the surface of classical and intermediate monocytes derived from healthy human blood.
Bexmarilimab inhibited the internalization of its natural ligand acetylated low-density lipoprotein into KG-1 cells and increased TNFα secretion from macrophages but did not impair phagocytic clearance.
Bexmarilimab did not induce significant cytokine release in human whole-blood cultures, did not contain nonsafe immunogenic glycans, or show any significant binding to human Fcγ receptors or complement pathway component C1q.
<i>In vivo</i>, bexmarilimab showed dose-dependent duration of monocyte Clever-1 receptor occupancy in cynomolgus monkeys but did not induce a cytokine storm up to a dose of 100 mg/kg.
</p><p>In conclusion, these data support the clinical development of bexmarilimab for the restoration of immune response in cancers.
</p></div>.

Related Results

Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Gastro-esophageal adenocarcinoma (GEAC) is a cancer with a poor prognosis and limited treatment options. Most patients present with metastatic disease, where systemic therapies off...
Systems-level immune profiling in children with solid tumors
Systems-level immune profiling in children with solid tumors
<p dir="ltr">Childhood cancer is a leading cause of disease-related death in children, and despite major improvements in survival over the past decades, around 15% of affecte...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Procedure for Western blot v1
Procedure for Western blot v1
Goal: This document has the objective of standardizing the protocol for Western blot. This technique allows the detection of specific proteins separated on polyacrylamide gel and t...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
A comprehensive review on IoT based smart cities
A comprehensive review on IoT based smart cities
A smart city uses information and communication technology to improve the utility, share knowledge with the public, and provide a strong sense of community support and local govern...

Back to Top